Roisin E. O'Cearbhaill reviews a phase 1/2 trial evaluating REGN5668, a MUC16×CD28 bispecific antibody, in combination with other targeted therapies for recurrent ovarian and endometrial cancers.
Roisin O’Cearbhaill, MD
Articles by Roisin O’Cearbhaill, MD